KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Other Operating Expenses (2016 - 2025)

Arbutus Biopharma's Other Operating Expenses history spans 13 years, with the latest figure at $268000.0 for Q3 2025.

  • For Q3 2025, Other Operating Expenses fell 22.09% year-over-year to $268000.0; the TTM value through Sep 2025 reached -$9.5 million, down 1092.2%, while the annual FY2024 figure was $2.6 million, 3704.35% up from the prior year.
  • Other Operating Expenses for Q3 2025 was $268000.0 at Arbutus Biopharma, up from -$12.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.9 million in Q4 2024 and bottomed at -$12.0 million in Q2 2025.
  • The 5-year median for Other Operating Expenses is $215000.0 (2022), against an average of -$311842.1.
  • The largest annual shift saw Other Operating Expenses surged 733.68% in 2022 before it tumbled 5775.36% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $193000.0 in 2021, then soared by 733.68% to $1.6 million in 2022, then crashed by 85.89% to $227000.0 in 2023, then skyrocketed by 732.6% to $1.9 million in 2024, then crashed by 85.82% to $268000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Other Operating Expenses are $268000.0 (Q3 2025), -$12.0 million (Q2 2025), and $272000.0 (Q1 2025).